Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

globenewswire

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer – NEWSnet – News… as it used to be

More Press Releases

May 4, 2026

Top 5 Cybersecurity Experts Defining the Modern Era

May 4, 2026

Buyers Brokers Only Celebrates 30 Years of the National Association of Exclusive Buyer Agents

May 4, 2026

Too Good To Be True: Top Bank Analyst Warns Hidden Risks Are Building Inside America’s Largest Banks

May 4, 2026

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Top 5 Cybersecurity Experts Defining the Modern Era

Buyers Brokers Only Celebrates 30 Years of the National Association of Exclusive Buyer Agents

Too Good To Be True: Top Bank Analyst Warns Hidden Risks Are Building Inside America’s Largest Banks

MyDataWork Launches Workspace for Data Workers Supporting Agentic AI Adoption